World first personalised cancer vaccine stops disease returning in major trial

A world-first personalised cancer vaccine has significantly reduced the risk of death and disease recurrence in a major trial. Scientists suggest these results could represent a turning point in cancer treatment, advancing the implementation of personalised medicine. The trial focused on melanoma, which is identified as the most aggressive form of skin cancer, resulting in approximately 2,600 deaths annually within the UK. This medical breakthrough offers a new approach to preventing the return of this deadly disease.